Open Nav

Cytox Ltd

  • Richard Pither, Cytox

To raise new funds in the $5-10m range to support clinical product development

  • Date:Wednesday, October 17
  • Time:3:45 PM - 4:00 PM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Cytox is a precision medicine information company whose mission is to transform how treatments are developed, people are screened and therapies are prescribed for the most prevalent neurological diseases, including Alzheimer’s disease. Together with leading academic and industrial partners, we are developing a simple and accurate genetic test to predict future risk of cognitive decline and Alzheimer’s Disease (AD). Our polygenic risk score (PRS) tests are being offered via third party genotyping laboratories and are available on a world-wide basis. The Cytox test is being offered in partnership with Thermo Fisher Scientific (Affymetrix) and comprises our proprietary variaTECT microarray, used together with Cytox SNPfitR™ software, supporting analysis with polygenic risk score (PRS) algorithms to identify at-risk individuals. Near-term commercial opportunities to identify subjects for clinical studies (Pharma and Academic consortia) are being developed.
  • Company Website:www.cytoxgroup.com
  • Company HQ City:Manchester
  • Company HQ Country:United Kingdom
  • CEO/Top Company Official:Dr Richard Pither
  • Year Founded:2013
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :variaTECT array with polygenic risk score analysis
  • Development Phase of Primary Product:Multiple Products in Market
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :N/A
  • Additional Information/Comments:Current diagnostic methods lack accuracy in early disease but it is widely acknowledged that this is a key population to include in therapeutic trials.The development of new Alzheimer's drugs has been hampered by the lack of an effective early diagnostic test, resulting in the cost of recruiting patients for clinical trials being prohibitively high. The availability of the Cytox test has the potential to transform the prospects for cost-effective identification of subjects for clinical trials. We will be raising new funds in order to build upon early commercial momentum that has been established with customers in both Pharma and Academia and also to pursue major opportunities in clinical product development and for the China market. Estimates of market size for a risk stratification assay for the Pharma licence and service market segment alone, are in the $500M per annum range. Beyond this, the clinical prognostic market opportunity is estimated to be greater than $2Bn per annum.
  • Previous and Current Investors:Catapult Ventures; SPARK Ventures; Wren Capital; OTIF
  • Size of Last Investment Round:$1.1M
  • Total Amount Raised to Date, In All Rounds:$11M
Speakers
Back